Altimmune Announces Initiation of RESTORE Phase II Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Altimmune, Inc. announced that it has enrolled the first patient in the RESTORE Phase II trial evaluating the efficacy and safety of pemvidutide in subjects with ALD.